~4 spots leftby Apr 2026

Psilocybin + Psychotherapy for Fibromyalgia

Recruiting in Palo Alto (17 mi)
+1 other location
KF
Overseen byKevin F Boehnke, PhD
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: Kevin Boehnke
Must not be taking: Antidepressants, Opioids, Benzodiazepines, others
Disqualifiers: Cardiovascular disease, Epilepsy, Diabetes, others
No Placebo Group
Prior Safety Data

Trial Summary

What is the purpose of this trial?

The pressing need for effective fibromyalgia (FM) treatments, the known safety of psilocybin therapy, and the mechanistic plausibility for potential benefit provide a backdrop for investigating psilocybin therapy as a treatment for FM. The primary objective of this study is to evaluate the clinical benefit of oral psilocybin in concert with psychotherapy to treat chronic pain symptoms in patients with FM.

Do I need to stop my current medications to join the trial?

Yes, you will need to stop taking certain medications. Participants cannot take psychoactive prescription medications regularly, including antidepressants, opioids, and medications with a primary centrally-acting serotonergic effect. If you are on such medications, you may need to taper off with your doctor's support before joining the trial.

What data supports the effectiveness of the treatment Psilocybin + Psychotherapy for Fibromyalgia?

There is no direct data on Psilocybin + Psychotherapy for fibromyalgia, but studies on similar treatments suggest potential benefits. For example, medicinal plants and natural products have shown significant improvements in pain, depression, and quality of life for fibromyalgia patients, indicating that alternative therapies might be effective.12345

Is psilocybin with psychotherapy safe for humans?

There is growing interest in using psilocybin with psychotherapy for chronic pain, and past users generally report neutral to positive perceptions of its benefits. However, specific safety data for this combination in fibromyalgia is not provided in the available research.12467

How does the drug TRP-8802 (Psilocybin) differ from other treatments for fibromyalgia?

TRP-8802 (Psilocybin) is unique because it combines psilocybin, a psychedelic compound, with psychotherapy to potentially address both the physical pain and psychological distress associated with fibromyalgia, unlike traditional treatments that often focus solely on pain relief.128910

Research Team

KF

Kevin F Boehnke, PhD

Principal Investigator

University of Michigan

Eligibility Criteria

Adults aged 25-64 with fibromyalgia for at least 3 months, stable in psychotherapy, non-smokers, and not using certain medications can join. They must avoid psychoactive substances before sessions and women of childbearing potential need effective birth control.

Inclusion Criteria

I can avoid nonprescription drugs and supplements for 7 days before each psilocybin session.
Participant must agree to consume approximately the same amount of caffeine-containing beverage (e.g., coffee, tea, cola) that he/she consumes on a usual morning, before arriving at the research unit on the mornings of TRP-8802 session days. If the participant does not routinely consume caffeinated beverages, he/she must agree to not do so on TRP-8802 session days.
Participant must be a non-smoker (tobacco).
See 20 more

Exclusion Criteria

Participant is currently in another clinical trial.
I am currently on antidepressant medication.
I am taking diabetes medication and have had low blood sugar episodes.
See 18 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive two doses of psilocybin: a 15 mg dose followed 2 weeks later by a 25 mg dose, in concert with psychotherapy

4 weeks
2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 months

Treatment Details

Interventions

  • Psychotherapy (Behavioral)
  • TRP-8802 (Psychedelic)
Trial OverviewThe trial tests the combination of oral psilocybin (a psychedelic compound) with psychotherapy to see if it helps reduce chronic pain in fibromyalgia patients. Participants will take psilocybin under controlled conditions alongside their ongoing therapy.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Open Label Oral PsilocybinExperimental Treatment2 Interventions
This is an open-label study, and participants who meet the inclusion and exclusion criteria will be eligible and invited to enroll. Enrolled participants are planned to receive 2 doses of psilocybin: a 15 mg dose followed 2 weeks later by a 25 mg dose. The total planned duration of the study for an individual participant from screening to last follow-up is approximately 8 months.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Kevin Boehnke

Lead Sponsor

Trials
2
Recruited
480+

TRYP Therapeutics

Lead Sponsor

Trials
4
Recruited
30+

Findings from Research

In a study involving 20 chronic pain patients with fibromyalgia, inhaled cannabis did not show significant analgesic effects compared to placebo, although the Bediol variety led to a 30% decrease in pain scores for some patients.
Cannabis containing THC increased pressure pain thresholds, but the presence of CBD appeared to reduce the overall pain-relieving effects of THC, highlighting complex interactions between these cannabinoids.
An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia.van de Donk, T., Niesters, M., Kowal, MA., et al.[2022]
In a double-blind, randomized pilot trial involving women with fibromyalgia, taking 6 g/day of Ganoderma lucidum (GL) for 6 weeks showed trends towards improved happiness and life satisfaction, as well as reduced depression, although these results were not statistically significant.
The study highlights the potential of GL as a complementary treatment for fibromyalgia symptoms, but emphasizes the need for further research to validate these preliminary findings due to limitations in the study design.
Ganoderma lucidum Effects on Mood and Health-Related Quality of Life in Women with Fibromyalgia.Pazzi, F., Adsuar, JC., Domínguez-Muñoz, FJ., et al.[2020]
A systematic review of 60 randomized controlled trials on complementary and alternative medicine (CAM) for fibromyalgia found that balneotherapy and mind-body therapies were effective in reducing FM pain.
Despite the promising results for some CAM therapies, many studies were preliminary with small sample sizes, indicating a need for larger, more robust trials to confirm these findings.
Complementary and alternative medicine in the treatment of pain in fibromyalgia: a systematic review of randomized controlled trials.Terhorst, L., Schneider, MJ., Kim, KH., et al.[2018]

References

An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. [2022]
Ganoderma lucidum Effects on Mood and Health-Related Quality of Life in Women with Fibromyalgia. [2020]
Complementary and alternative medicine in the treatment of pain in fibromyalgia: a systematic review of randomized controlled trials. [2018]
Efficacy and safety of medicinal plants or related natural products for fibromyalgia: a systematic review. [2022]
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. [2021]
Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia. [2023]
Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry. [2023]
Effect of adding medical cannabis to analgesic treatment in patients with low back pain related to fibromyalgia: an observational cross-over single centre study. [2019]
[CHARACTERISTICS OF MEDICAL CANNABIS USAGE AMONG PATIENTS WITH FIBROMYALGIA]. [2020]
Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia. [2021]